EIT Pharma Showcases Promising Lonafarnib Data at EASL Congress 2026

EIT Pharma has recently made significant contributions to the medical community by presenting new analyses of its lonafarnib program during the EASL Congress 2026, held in Barcelona, Spain, from May 27 to May 30. This major event served as a platform to discuss the latest advancements in chronic hepatitis D (CHD) treatment, focusing on unmet medical needs and potential patient outcomes.

The phase 3 D-LIVR study, recognized as the largest clinical trial in chronic hepatitis D, has shed light on the efficacy of lonafarnib. EIT Pharma’s decision to revisit this promising therapeutic option stems from the critical need for effective treatments for CHD, where limited alternatives have been available thus far. According to recent findings, lonafarnib stands out as the only oral medication currently in late-stage development specifically for this condition.

Under the leadership of CEO Dr. Leen Kawas, EIT Pharma has initiated a patient-centered approach to drug development, showcasing their commitment to addressing high unmet needs in the healthcare landscape. The analyses presented at the congress include pivotal findings from the D-LIVR study, which enrolled over 400 subjects across 21 countries, marking a significant step forward in the ongoing battle against chronic hepatitis D.

One of the highlighted oral presentations covered results elucidating the impact of lonafarnib and ritonavir in conjunction with peg-interferon alfa. This study demonstrated substantial histological improvements and resolutions of inflammation associated with chronic hepatitis D. Dr. Saeed Hamid, who presented these results, emphasized the potential of these findings to reshape treatment protocols for patients grappling with this progressive liver disease.

Additionally, a poster presentation was delivered on another aspect of the D-LIVR trial. The findings indicated that combinations of lonafarnib/ritonavir, regardless of whether peginterferon was included, could yield rapid and enduring responses in chronic hepatitis D patients. This was presented during the